CURRICULUM VITAE
Kristen B. Bresnehan PharmD
Kristen B. Bresnehan PharmD
Associate Professor
Department of School of Pharmacy Administration
Division of Administration
Department of School of Pharmacy Administration
Division of Administration
OFFICE ADDRESS: |
Health Research Center |
8701 Watertown Plank Rd |
Milwaukee, WI 53226 |
Phone: 414-955-2888 |
Email: kbunnell@mcw.edu |
EDUCATION: |
09/01/2004 - 05/01/2009 Doctor of Pharmacy, Northeastern University, Boston, MA |
08/01/2015 - 05/01/2017 Certificate in Clinical Research Methods, University of Illinois at Chicago School of Public Health, Chicago, IL |
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: |
07/01/2009 - 06/30/2010 Pharmacy Residency, University of Texas at Austin College of Pharmacy & Seton Family of Hospitals, Austin, TX |
07/01/2010 - 06/30/2011 Pharmacy Residency in Critical Care, Virginia Commonwealth University Health System, Richmond, VA |
07/01/2015 - 06/30/2017 Research Fellow in Infectious Diseases Pharmacotherapy, University of Illinois at Chicago College of Pharmacy, Chicago, IL |
FACULTY APPOINTMENTS: |
07/24/2017 - Present Assistant Professor, Clinical Sciences, Medical College of Wisconsin Pharmacy School, 8701 Watertown Plank Road, Milwaukee, WI 53226 |
01/21/2019 - Present Assistant Professor (Secondary Appointment), Medicine, Infectious Diseases, Medical College of Wisconsin, Milwaukee, WI |
EDUCATIONAL ADMINISTRATIVE APPOINTMENTS: |
04/01/2018 - Present Course Director, PHAR 564 Infectious Diseases II, School of Pharmacy, Medical College of Wisconsin |
10/01/2018 - Present Course Director, PHAR 682 Advanced Infectious Diseases Elective, School of Pharmacy, Medical College of Wisconsin |
HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS: |
08/01/2011 - 06/05/2015 Clinical Pharmacy Specialist, Critical Care, Pharmacy Services, Rhode Island Hospital |
09/01/2017 - 12/01/2018 Clinical Pharmacist, Critical Care, Pharmacy Services, Froedtert Hospital |
01/01/2019 - Present Clinical Pharmacist, Infectious Diseases, Pharmacy Services, Froedtert Hospital, 9200 West Wisconsin Avenue, Milwaukee, WI 53226 |
SPECIALTY BOARDS AND CERTIFICATION: |
Board Certified | Issue Date | Expiration |
Board Certified Critical Care Pharmacist (BCCCP) | 07/01/2016 | 12/31/2023 |
Board Certified Infectious Disease Pharmacist (BCIDP) | 12/31/2019 | 12/31/2026 |
PEER REVIEWED WORKSHOPS/PRESENTATIONS: |
Regional |
Bunnell K, Shea K, Jaso TM, Evaluation of empiric antimicrobial prescribing for febrile neutropenia, Central Texas Clinical Research Forum, Austin, Texas, 05/01/2010 - Present |
BIBLIOGRAPHY |
Refereed Journal Publications/Original Papers |
1. Bunnell KL, Danziger LH, Johnson S. Economic Barriers in the Treatment of <i>Clostridium difficile</i> Infection With Oral Vancomycin. Open Forum Infect Dis. 2017;4(2):ofx078. PMCID: PMC5472230 |
2. Bunnell KL, Zullo AR, Collins C, Adams CA Jr. Methicillin-Resistant Staphylococcus aureus Pneumonia in Critically Ill Trauma and Burn Patients: A Retrospective Cohort Study. Surg Infect (Larchmt). 2017;18(2):196-201. |
3. Wenzler E, Bunnell KL, Bleasdale SC, Benken S, Danziger LH, Rodvold KA. Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration. Antimicrob Agents Chemother. 2017 Jul;61(7). PMCID: PMC5487628 |
4. Bunnell KL, Vibhakar S, Glowacki RC, Gallagher MA, Osei AM, Huhn G. Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection. Pharmacotherapy. 2016 Sep;36(9):e148-53. |
5. Brophy GM, Mazzeo AT, Brar S, Alves OL, Bunnell K, Gilman C, Karnes T, Hayes RL, Bullock R. Exposure of cyclosporin A in whole blood, cerebral spinal fluid, and brain extracellular fluid dialysate in adults with traumatic brain injury. J Neurotrauma. 2013 Sep 01;30(17):1484-9. PMCID: PMC3751213 |
6. Bunnell K, Pucci F. Levetiracetam-induced neutropenia following traumatic brain injury. Brain Inj. 2015;29(1):115-7. |
7. Guinta MM, Bunnell K, Harrington A, Bleasdale S, Danziger L, Wenzler E. Clinical and economic impact of the introduction of a nucleic acid amplification assay for Clostridium difficile. Ann Clin Microbiol Antimicrob. 2017 Dec 04;16(1):77. PMCID: PMC5713042 |
8. Wenzler E, Bunnell KL, Danziger LH. Clinical use of the polymyxins: the tale of the fox and the cat. Int J Antimicrob Agents. 2018 May;51(5):700-706. |
9. Bunnell KL, Pai MP, Sikka M, Bleasdale SC, Wenzler E, Danziger LH, Rodvold KA. Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects. Antimicrob Agents Chemother. 2018 Apr;62(4). PMCID: PMC5913990 |
10. Bunnell KL, Aldossari A, Perkins C, Schriever C, Chiampas TD, Young JD, Patel MC, Badowski M. Immunologic and Virologic Outcomes of Obese and Nonobese Incarcerated Adults on Antiretroviral Therapy for HIV Infection. J Int Assoc Provid AIDS Care. 2018;17:2325957417752261. PMCID: PMC6748539 |
11. Trick WE, Sokalski SJ, Johnson S, Bunnell KL, Levato J, Ray MJ, Weinstein RA. Effectiveness of Probiotic for Primary Prevention of Clostridium difficile Infection: A Single-Center Before-and-After Quality Improvement Intervention at a Tertiary-Care Medical Center. Infect Control Hosp Epidemiol. 2018 Jul;39(7):765-770. |
12. Wenzler E, Bleasdale SC, Sikka M, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA, Antibacterial Resistance Leadership Group. Phase I Study To Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants. Antimicrob Agents Chemother. 2018 Aug;62(8). PMCID: PMC6105781 |
13. Wenzler E, Meyer KM, Bleasdale SC, Sikka M, Mendes RE, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA. <i>Ex Vivo</i> Urinary Bactericidal Activity and Urinary Pharmacodynamics of Fosfomycin after Two Repeated Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Subjects. Antimicrob Agents Chemother. 2020 Jan 27;64(2). PMCID: PMC6985713 |
14. Long A, Bevry M, Wellborn A, Bunnell KL. Pain in the patella: updates in the management of osteomyelitis. Journal of the Pharmacy Society of Wisconsin. May-June 2020;16-19. |
15. Bunnell KL, Revolinski S, Wainaina N. Chloroquine and hydroxychloroquine: what does the evidence say for use in COVID-19? Journal of the Pharmacy Society of Wisconsin. May-June 2020;26-29. |
16. Bunnell K, Duong A, Ringsred T, Mian A, Bhathena S. Aminopenicillins for treatment of ampicillin-resistant enterococcal urinary tract infections. Am J Health Syst Pharm. 2022 Jun 23;79(13):1056-1065. |
17. SantibaƱez M, Bunnell K, Harrington A, Bleasdale S, Wenzler E. Association Between Estimated Pharmacokinetic/Pharmacodynamic Predictions of Efficacy and Observed Clinical Outcomes in Obese and Nonobese Patients With <i>Enterobacteriaceae</i> Bloodstream Infections. Open Forum Infect Dis. 2019 Oct;6(10):ofz400. PMCID: PMC6790397 |
18. Bunnell KL, Wenzler E, Harrington AT, Danziger LH. Impact of Clinical and Laboratory Standards Institute breakpoint changes on susceptibility rates of cephalosporins in uncomplicated urinary tract infections caused by Enterobacteriaceae. Diagn Microbiol Infect Dis. 2018 Apr;90(4):335-336. |
19. Roig J, Sorenson J, Staffin M, Amrhein A, Bunnell K.. Tebipenem pivoxil hydrobromide: review of a new oral carbapenem in development. Journal of the Pharmacy Society of Wisconsin. JPSW May-June 2021. |
20. Schmidt AL, Maistelman E, Bunnell K.. Viral myocarditis Journal of the Pharmacy Society of Wisconsin. JPSW July-August 2022. |
21. Gandhi K, Wrzesinski M, Bunnell K, Gibble A. Oral antibiotic step-down therapy for nonstaphylococcal gram-positive bloodstream infections Diagnostic Microbiology and Infectious Disease. December 2023;107(4). |
22. Badowski M, Kassem S, Labedz M, Taylor C, Bunnell K, Hall A, Darnell H, Huesgen E. Virologic outcomes of antiretroviral therapy in patients with HIV-1 following bariatric surgery: A case series and review of the literature International Journal of STD and AIDS. 2023. |
Editorials, Letters To Editor, Other |
1. Pneumococcal vaccine updates: PCV15 and PCV20. Ledvina KR, Bunnell K. American College of Clinical Pharmacy ID PRN Spring Newsletter. April/May 2022. |
2. Updated asymptomatic bacteriuria guidelines from the Infectious Diseases Society of America. "Papers That May Change Practice" section in Society of Infectious Diseases Pharmacists Newsletter. Summer 2019. |
Non-Refereed Journal Publications/Original Papers |
1. Solofra C, Sanok R, Lindstrom R, Bunnell K. Get PrEPared for HIV Prophylaxis Pharmacy Times Health Systems Edition. May 2019 Volume 8 Issue 3. |
2. Woulfe E, Vu T, Schaack H, Dyer J, Bunnell K. New Antimicrobials Expand Treatment Options Pharmacy Times Health Systems Edition. September 2019, Volume 8, Issue 5. |
3. Bunnell KL. 5 Emerging Infections to Watch out for in 2018. Contagion 2018;3(1). URL: https://www.contagionlive.com/view/5-emerging-infections-to-watch-out-for-in-2018. |
Abstracts |
1. Bunnell KL, Wenzler E, Danziger LH, Rodvold KA. Clearance of ceftazidime-avibactam in an in vitro continuous venovenous hemodialysis model [poster 821]. ID Week Annual Meeting, San Diego, CA, October 2017
|
2. Wenzler E, Bleasdale SC, Sikka MK, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA. Phase I study to evaluate the pharmacokinetics of two dosing regimens of oral fosfomycin tromethamine in healthy adult participants. ID Week Annual Meeting, San Diego, CA, October 2017.
|
3. Bleasdale SC, Wenzler E, Sikka MK, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA. Phase I study to evaluate the safety and tolerability of two dosing regimens of oral fosfomycin tromethamine in healthy adult participants. ID Week Annual Meeting, San Diego, CA, October 2017.
|
4. Horn K, Bunnell KL, Danziger LH, Wenzler E. In vitro double-disk diffusion synergy of solithromycin against Gram negative and positive pathogens. American Society of Microbiology MICROBE Meeting. New Orleans, LA. June 2017 |
5. Bunnell KL, Sikka M, Bleasdale SC, Wenzler E, Pai MP, Danziger LH, Rodvold KA. Pharmacokinetics of fixed dose telavancin in obese and non-obese adult subjects. European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria. April 2017. |
6. Murdock R, Benken S, Petzel-Gimbar R, Danziger LH, Bunnell KL. qSOFA and SIRS in the identification of patients with infection. American Society of Health System Pharmacists Midyear Conference. Las Vegas, NV. December 2016. |
7. Badowski M, Kassem S, Taylor C, McKarney L, Janelle J, Lamadrid E, Bunnell KL, Huesgen E. Virologic outcomes of antiretroviral therapy in HIV-1 infected patients following bariatric surgery: a case series
ID Week 2016. New Orleans, LA. October 2016. |
8. Bunnell KL, Trick W, Danziger LH, Johnson S. Toxin identification and clinical outcomes in patients with Clostridium difficile infection: a systematic review and meta-analysis. European Congress of Clinical Microbiology and Infectious Diseases. Amsterdam, Netherlands. April 2016. |
9. Bunnell KL, Aldossari A, Perkins C, Badowski M. Immunologic and virologic outcomes of obese and non-obese incarcerated adults. European Congress of Clinical Microbiology and Infectious Diseases. Amsterdam, Netherlands. April 2016. |
10. Bunnell KL, Zullo A, Adams C, Berard-Collins C. Methicillin-resistant Staphylococcus aureus pneumonia in critically ill trauma patients. Society of Critical Care Medicine Congress. Orlando, Florida. February 2016. |
11. Bunnell KL, Lee K, Stevens M, Voils S. Antimicrobial prophylaxis and infection following total artificial heart (TAH) implantation. Society of Critical Care Medicine Congress. Houston, TX. February 2012. |
12. Polenska J, Hraba T, Bunnell KL. Antimicrobial stewardship practices of consultant pharmacists in Wisconsin long term care facilities. American Society of Health-System Pharmacists Midyear Annual Meeting. Las Vegas, NV. December 2019. |
13. Bunnell KL, Wenzler E, Rodvold KA. Evaluation of clearance equations in continuous renal replacement therapy with an in vitro model. Society of Critical Care Medicine Congress. San Antonio, Texas. February 2018. |
14. Gandhi K, Wrzesinski M, Bunnell K, Long A, Hutzley V, Hamilton R, Sundack J, Gibble A. Oral antibiotic stepdown therapy for non-staphylococcal gram-positive bloodstream infections. ID Week. October 2021 (virtual).
|
15. Wermers M, Bunnell KL, Gibble A. Impact of beta-lactam allergy assessment on preoperative antibiotic selection. Making a Difference in Infectious Diseases (MAD-ID) Annual Conference. May 2021 (virtual)
|
16. Schmidt M, Bunnell KL. Cost-effectiveness analysis of dalbavancin and comparator antibiotics for treatment of bone and joint infections from a healthcare system perspective. American Society of Health-System Pharmacists Midyear Conference. December 2020 (virtual). |
17. Bartley N, Saavedra A, Gibble A, Her-Cilley S, Braithwaite K, Bunnell K. Risk factors for methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa in hospitalized patients with community acquired pneumonia. Pharmacy Society of Wisconsin Educational Conference. Madison, WI. April 2022
|
18. Sielatchom Noubissie L, Bunnell K, Bevry M, Dworak L, Hood A, Ward J, Glienke A. Implementation of a pharmacist-driven policy for the appropriate use of stress ulcer prophylaxis in non-critically ill patients. Great Lakes Residency Conference. April 2021. |
19. Serratore CD, Wrzesinski M, Bunnell K, Spillane J, Hart M. Assessment of Diagnosis and Treatment of Urinary Tract Infections in Primary Care. Great Lakes Pharmacy Residency Conference. Virtual. April 2020. |
20. Hutzley V, Gibble A, Powell K, Wainaina N, Bunnell K, Daniels A, Wrzesinski M. Impact of a pharmacy-driven beta-lactam allergy assessment on allergy documentation optimization. Wisconsin Pharmacy Residency Conference at Pharmacy Society of Wisconsin. Virtual. April 2020. |
Non-Peer Reviewed Educational Products |
1. Selecting the Correct Statistical Test. Pharmacy Residency Research Toolkit module. Vizient Pharmacy Network. October 2019. |